Mutations in the Epstein-Barr virus latent membrane protein-1 (BNLF-1) gene in spontaneous lymphoblastoid cell lines: Effect on in vitro transformation associated parameters and tumorigenicity in SCID and nude mice

Journal of Clinical Pathology - Clinical Molecular Pathology

Volumn 49, Issue 5, 1996, Pages

  Sandvej, Kristian ^a   Munch, Mette ^b   Hamilton Dutoit, Stephen ^c  

^a University Institute of Pathology Arhus   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Epstein Barr virus; Latent membrane protein 1; Spontaneous lymphoblastoid cell lines

Indexed keywords

CELL MEMBRANE PROTEIN;

ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LYMPHOBLASTOID CELL LINE; NUDE MOUSE; POINT MUTATION; PRIORITY JOURNAL; VIRUS CARCINOGENESIS;

EID: 0029819226     PISSN: 13552910     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.49.5.m290     Document Type: Article

References (41)

1. Henle G, Henle W, Diehl V. Relation of Burkitt's tumour-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA 1968;59:94-101.
2. Zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, et al. EBV DNA in biopsies of Burkitt's lymphoma and anaplastic carcinoma of the nasopharynx. Nature 1970;228:1056-8.
3. Young L, Dawson C, Clark D, Rupani H, Bussen P, Turz T, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988;69:1051-65.
4. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young L. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991;ii:320-2.
5. Pallesen G, Hamilton-Dutoit SJ, Zhou XG. The association of Epstein-Barr virus (EBV) with T cell lymphoproliferation and Hodgkin's disease: Two new developments in the EBV field. Adv Cancer Res 1993;62:179-239.
6. Hanto DW, Gajl-Peczalska KJ, Frizzera G, Arthur DC, Balfour HH, McClain K, et al. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative disease occurring after renal transplantation. Clinical pathological, and virological findings and implications for therapy. Ann Surg 1983;198:356-69.
7. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB, Karkov J, Black F, Skinhoj P, et al. AIDS related lymphomas. Histopathology, immunophenotype and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridisation. AmJPathol 1991;138:149-63.
8. Nilson K. The nature of lymphoid cell lines and their relationship to the virus. In: Epstein MA, Achong BG (eds). The Epstein-Barr virus. Berlin: Springer Verlag, 1979: 227-81.
9. Kerr BM, Lear AL, Rowe M, Groom-Carter D, Young LS, Rookes SM, et al. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology 1992; 187:189-201.
10. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein-1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993;90:9150-4.
11. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:831-40.
12. Fâhraeus R, Rymo L, Rhim JS, Klein G. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 1990;345:447-9.
13. Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990;344:777-80.
14. Hammerschmidt W, Sugden B, Baichwal VR. The transforming domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels. J Virol 1989;63:2469-75.
15. Moorthy RK, Thorley-Lawson DA. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of Rat-1 fibroblasts. J Virol 1993;67:1638-46.
16. Wilson JB, Weinberg W, Johnson R, Yuspa S, Levine AJ. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 1990;61:1315-27.
17. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP-1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 1992;7:1775-82.
18. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP-1 gene in chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: Cell-type independent-induction of CD23, CD21 and ICAM-1. Leukemia 1993;7:104-12.
19. Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, Klein G, et al. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP-1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 1991;72:2399-409.
20. Chen ML, Tsai CN, Liang CL, Shu CH, Huang CR, Sulitzeanu D, et al. Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 1992;7:2131-40.
21. Hu LF, Chen F, Zheng X, Ernberg I, Cao SL, Christensson B, et al. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 1993;8:1575-83.
22. Sandvej K, Peh SC, Andresen B, Pallesen G. Identification of potential hot-spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV associated diseases: High frequency of a 30 bp deletion in Malaysian and Danish peripheral T-cell lymphomas. Blood 1994;84:4053-60.
23. Miller WE, Edwards RH, Walling DM, Raab-Traub N. Sequence variation in the Epstein-Barr virus latent membrane protein 1. J Gen Virol 1994;75:2729-40.
24. Sample J, Kieff EF, KiefT ED. Epstein-Barr virus types 1 and 2 have nearly identical LMP-1 transforming genes. J Gen Virol 1994;75:2741-6.
25. Moorthy RK, Thorley-Lawson DA. Biochemical, genetic and functional analysis of the phosphorylation sites on the Epstein-Barr virus-encoded oncogenic latent membrane protein LMP-1. J Virol 1993;67:2637-2645.
26. Li SN, Chang YS, Liu ST. Effect of a 10 amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-barr virus. Oncogene 1996;12:2129 -35.
27. Hansen H, Morling N. Paternity testing with VNTR DNA systems II. Evaluation of 271 cases of disputed paternity with the VNTR systems D2S44, D5S43, D7S21, D7S22 and D12S\ \.IntJLegMedl993;l06:l97-202.
28. Morling N, Hansen H. Paternity testing with VNTR DNA systems I. Matching criteria and population frequencies of the VNTR systems D2S44, D5S43, D7S43, D7S21, D7S22 and D12S11 in Danes. Im J Leg Med 1993;106: 189-96.
29. Nellemann L, Mol 1er A, Morling N. PCR typing of DNA fragments of the short tandem repeat (STR) system HUMTHO1 in Danes and Greenland Eskimoes. Forensic Scilnt 1994;68:45-51.
30. Thyman M, Nellemann LJ, Masumba G, Irgens-M011er L, Morling N. Analysis of the locus D1S80 by amplified fragments length polymorphism technique (AMRFLP). Frequency distribution in Danes. Intra and inter laboratory reproducibility of the technique. Forensic Sci Int 1993;60: 47-56.
31. Vindelev LL.Flow microfluorometric analysis of nuclear DNA in cells from solid tumours and cell suspensions. VirchowsArch B Cell Palhol 1977;24:227-42.
32. Sandvej K, Krenacs L, Hamilton-Dutoit S, Rindum J, Pindborg JJ, Pallesen G. Epstein-Barr virus latent and replicative gene expression in oral hairy leukoplakia. Histopathology 1992;20:387-95.
33. Kunimoto M, Tamura S, Tabata T, Yoshie O. One-step typing of Epstein-Barr virus by polymerase chain reaction: predominance of type 1 virus in Japan. J Gen Viral 1992;73:455-61.
34. Dambaugh T, Hennessy K, Chamnankit L, Kieff E. U2 region of Epstein-Barr virus DNA may encode EpsteinBarr nuclear antigen 2. Proc Nat! Acad Sci USA 1984;81:7632-6.
35. Hudson GS, Farrell PJ, Barrell BG. Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95.8. J Virol 1985;S3:528-35.
36. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, et al. Deletion within the LMP-1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 1993; 82:2937-42.
37. Knecht H, Raphael M, McQuain C, Rothenberger S, Pihan G, Camilleri-Broët S, et al. Deletion variants within the NF-KB activation domain of the LMP-1 oncogene prevail in acquired immunodeficiency syndrome-related large-cell lymphomas and human immunodeficiency virus-negative atypical lymphoproliferetions. Blood 1996;87:876-81.
38. Huen DS, Henderson SA, Groom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP-1) mediates activation of NF-KB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmatic domain. Oncogene 1995;10:549-60.
39. Trivedi P, Hu LF, Chen F, Christensson B, Masucci MG, Klein G. Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Ear J Cancer 1994;30A:84-8.
40. Rowe M, Pilon MP, Huen DS, Hardy R, Groom-Carter D, Lundgren E. Upregulation of BCL-2 by the Epstein-Barr virus latent membrane protein LMP 1: a B-cell-specific responce that is delayed relative to NF-KB activation and to induction of cell surface markers. J Virol 1994;68:5602-12.
41. Cooper DN, Krawczak M. Human gene mutation. Oxford: Bios Scientific Publishers, 1993:179-85.